Xenetic Biosciences, Inc. (NASDAQ:XBIO) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

BRIEF

published on 09/11/2024 at 15:05, 2 months 9 days ago

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Xenetic Biosciences H.C. Wainwright Immune-oncology Investment Presentation Jim Parslow
PRESS RELEASE

published on 09/11/2024 at 15:00, 2 months 9 days ago

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Xenetic Biosciences presented at H.C. Wainwright 26th Annual Global Investment Conference. The biopharmaceutical company focuses on immune-oncology technologies for hard-to-treat cancers

Xenetic Biosciences Biopharmaceutical Immune-oncology JTC Team Cancers
BRIEF

published on 08/14/2024 at 14:05, 3 months 6 days ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Financial Results Clinical Development Biopharmaceutical Oncology Program Xenetic
PRESS RELEASE

published on 08/14/2024 at 14:00, 3 months 6 days ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. reports financial results for Q2 2024, focusing on DNase-based oncology program in preclinical studies with data due before year end. Ended quarter with $7.3M cash

Financial Results Xenetic Biosciences Cash Balance DNase-based Oncology Program Preclinical Studies
BRIEF

published on 05/22/2024 at 23:05, 5 months 29 days ago

Xenetic Biosciences, Inc. Announces Executive Leadership Transition

Xenetic Biosciences Oncology Clinical Development Executive Leadership James Parslow
PRESS RELEASE

published on 05/22/2024 at 23:00, 5 months 29 days ago

Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Xenetic Biosciences appoints James F. Parslow as interim CEO. The company focuses on innovative immune-oncology technologies for hard-to-treat cancers

Xenetic Biosciences Clinical Development Pancreatic Carcinoma James Parslow Immune-oncology Technologies
BRIEF

published on 05/10/2024 at 14:35, 6 months 10 days ago

Xenetic Biosciences Reports Q1 2024 Financial Results and Business Progress

Financial Results Xenetic Biosciences Oncology Program DNase-based Therapy Preclinical Studies
PRESS RELEASE

published on 05/10/2024 at 14:30, 6 months 10 days ago

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. reports financial results for Q1 2024 and progress on DNase-based oncology program, including ongoing preclinical studies and funds of $7.8 million

Financial Results Xenetic Biosciences DNase-based Oncology Program Preclinical Studies Cash Reserves
BRIEF

published on 03/22/2024 at 13:05, 7 months 30 days ago

Xenetic Biosciences, Inc. Presents Full Year 2023 Financial Performance and Development Progress

Financial Results Xenetic Biosciences Biopharmaceuticals Oncology Program DNase Platform
PRESS RELEASE

published on 03/22/2024 at 13:00, 7 months 30 days ago

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Xenetic Biosciences reports financial results for 2023, highlighting progress on DNase-based oncology program leading to Phase 1 study for pancreatic carcinoma & solid tumors, ending year with $9.0 million

Financial Results Xenetic Biosciences Solid Tumors DNase-based Oncology Program Pancreatic Carcinoma

Accesswire

Published on 11/21/2024 at 13:30, 24 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 24 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 54 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 54 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 54 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 39 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 19 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 39 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 47 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 54 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 56 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 34 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 9 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 9 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE